1. Roehrborn, C. G., McConnell, J., Bonilla, J., Rosenblatt, S.,Hudson, P. B., Malek, G. H. et al: Serum prostate specificantigen is a strong predictor of future prostate growth in menwith benign prostatic hyperplasia. PROSCAR long-term effi-cacy and safety study. J Urol, 163: 13, 2000

2. Sakr, W. A., Grignon, D. J., Haas, G. P., Heilbrun, L. K., Pontes,J. E. and Crissman, J. D.: Age and racial distribution of pros-tatic intraepithelial neoplasia. Eur Urol, 30: 138, 1996

DOI: 10.1097/01.ju.0000169211.49050.8f

ERRATUM

PROGNOSTIC VALUE OF ANEMIA IN METASTATIC PROSTATE CANCER

Volume 172, Number 6, pages 2213–2217: The correct quartiles of hemoglobin in patients with newly diagnosedmetastatic prostate cancer were 12 or less, 12.1 to 13.7, 13.8 to 14.7, and above 14.7 gm/dl. Thus anemia was lesscommon than we reported, as 25% and not 50% of patients had anemia as defined by a hemoglobin of less than 12gm/dl. The associations between anemia and other baseline covariates, and between anemia and survival,progression-free survival, nonprostate cancer death and PSA normalization are correct. The hazard ratios reportedrepresented an analysis that compared outcomes in patients with hemoglobin 10.1 or less, 10.2 to 12, 12.1 to 13.4,and greater than 13.4.

LETTERS TO THE EDITOR1156